
S&P TEST

SWOT & PESTLE.com

AMGEN SWOT & PESTLE ANALYSIS

© Barakaat Consulting - An Ezzy IT Consulting Business

This is a licensed product and is not to be photocopied or distributed. All rights reserved. Unauthorized reproduction is strictly prohibited. Research is based on best available materials and resources. Topurchase reprints of this document, please email support@swotandpestle.com.

Company Name : Amgen

Company Sector : Pharmaceutical

Operating Geography : United States, North America, Global

About the Company :

Amgen is a leading global biotechnology company headquartered in Thousand Oaks, California. Since its establishment in 1980, Amgen has been dedicated to discovering, developing, manufacturing, and delivering innovative human therapeutics. With a mission to extend and improve the lives of patients, Amgen focuses on breakthrough medicines. As of 2023, Operating in over 100 countries, Amgen has a workforce of more than 19,000 employees. The company's diverse product portfolio encompasses a wide range of therapies for various diseases. In the field of oncology, Amgen offers highly regarded cancer treatments such as Neulasta and Enbrel. For hematology, their notable drugs include Aranesp and Epogen, addressing anemia. In the cardiovascular space, Amgen provides medications like Repatha and Prolia for managing high cholesterol and osteoporosis respectively. Additionally, Amgen offers immunology treatments such as Humira and Otezla for conditions like rheumatoid arthritis and psoriasis. As a research-driven organization, Amgen places significant investments in the discovery and development of new therapies.

Amgen's unique selling proposition lies in their commitment to developing innovative therapies that extend and improve lives. They aim to be the leading biotechnology company, driven by science, setting the standard for quality, safety, and efficacy. Through groundbreaking research and a patient-centric approach, they strive to make a meaningful impact on healthcare globally and address unmet medical needs.

Revenue :

US\$ 26.3 Billion – FY ended December 31, 2022 (year-on-year growth 1%)

US\$ 26.0 Billion – FY ended December 31, 2021

SWOT Analysis :

The SWOT Analysis for Amgen is given below:

Strengths	Weaknesses
<ol style="list-style-type: none"> 1.Regularly innovating and developing new products. 2.Expansion of global footprint with strong growth in APAC region 3.Advancing drug discovery- embracing a biology-first approach 4.Promising product portfolio with strong growth potential 5.World's largest independent biotechnology firm 6.Consistent increase in shareholder returns over the years 	<ol style="list-style-type: none"> 1.Sales of some most popular products are falling.
Opportunities	Threats
<ol style="list-style-type: none"> 1.There are still many life-threatening diseases that exist with no cure which can be developed 2.Increase in Healthcare expenditure of countries 3.Achieving innovative growth through strategic acquisitions 4.Advancing first-in-class medicines to address unmet needs in key therapeutic areas 5.Establishing an industry-leading Biosimilars Business to foster long-term growth: 	<ol style="list-style-type: none"> 1.Sales affected due to third-party payers including government and US legislation 2.The protection provided by patents is limited and can be challenged by competitors 3.Consolidation of private payers leading to concentration of sales and pricing pressures

PESTLE Analysis :

The PESTLE Analysis for Amgen is given below:

Political	Economical
1.Challenges of government pricing regulation in the biotechnology industry 2.Impact of Russia-Ukraine war	1.Global trade and international trade agreements affect the industry's trade relationship between countries. 2.Impact of global economic conditions on the pharmaceutical industry
Social	Technological
1.Aging Baby Boomer population in US 2.Impact of lifestyle changes on the prevalence of common diseases	1.Revolutionizing biopharmaceutical manufacturing through the advancement of single-use systems: 2.Advancing biomanufacturing process 3.Significance of track and trace systems
Legal	Environmental
1.Regulations by government authorities across jurisdictions in pharma development and marketing: 2.Uncertainty related to U.S. federal coverage and reimbursement policies	1.Driving towards a sustainable future

Please note that our free summary reports contain the SWOT and PESTLE table contents only.

The complete report for **Amgen** SWOT & PESTLE Analysis is a paid report at **15.53 U.S.D.**

Buy Now

* By clicking on "Buy Now" you agree to accept our "Terms and Conditions."



S&P

SWOT & PESTLE.com

SWOT & PESTLE.com is a leading strategy research portal covering detailed Strengths, Weaknesses, Opportunities, Threats (SWOT) and Political, Economic, Social, Technological, Legal and Environmental (PESTLE) analysis of leading industry sectors and organizations across the globe. Our full and comprehensive collection on SWOT and PESTLE has been written by our team of professional analysts consisting of MBA's, CFA's and industry experts. Our analysis has helped businesses, researchers and scholars with valuable insights to make strategic decisions and take their research forward.

We at SWOT & PESTLE.com aim to aid the understanding of the multifaceted business world by presenting a list of diverse companies from across the globe. Business organizations today cannot function in ways that ignore the surroundings that they are set in. SWOT & PESTLE.com makes a keen observation into this aspect and accounts for factors affecting such businesses.

Copyright Notice

The information provided in the SWOT and PESTLE research reports on www.swotandpestle.com are from publicly available documents and sources which are deemed reliable. Further the reports contain analysis and views from the SWOT & PESTLE.com research and analyst team which consists of qualified experts. While every attempt has been made to ensure completeness, accuracy and reliability of the analysis, Barakaat Consulting and its associate websites cannot be held responsible or legal liable for omissions or errors in our reports or on any of our pages.

(C)2024 Barakaat Consulting. All rights reserved. This report may not be reproduced, copied or redistributed, in whole or in part, in any form or by any means, without the express written consent of Barakaat Consulting. Also, Barakaat Consulting is the sole copyright owner of this report, and any use of this report by any third party is strictly prohibited without a license expressly granted by Barakaat Consulting. Neither all nor any part of the contents of this report, or any opinions expressed herein, can be used in advertising, press releases, or promotional materials without prior written approval from Barakaat Consulting. Any violation of Barakaat Consultings rights in this report will be executed to the fullest extent of the law, including the pursuit of monetary damages and injunctive relief in the event of any breach of the foregoing restrictions.

Client Support:
support@swotandpestle.com